<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
GILD
Gilead
$
()


  • Unusually active option classes on open April 9th

    4/9/2024 - 09:41am
  • Fly Insider: Xilio, Aerovate among week’s notable insider trades

    4/8/2024 - 15:18pm
  • Nurix Therapeutics announces extension of collaboration with Gilead

    4/2/2024 - 07:12am
  • Gilead announces FDA approval for Vemlidy sNDA

    3/28/2024 - 08:49am
  • Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal

    3/28/2024 - 07:22am
  • Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301

    3/28/2024 - 07:13am
  • Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301

    3/28/2024 - 07:10am
  • Unusually active option classes on open March 22nd

    3/22/2024 - 09:41am
  • Gilead completes acquisition of CymaBay

    3/22/2024 - 09:27am
  • Gilead says CymaBay deal to lower 2024 EPS by $3.35-$3.45

    3/22/2024 - 09:27am
  • JPMorgan biotech/pharma analysts hold an analyst/industry conference call

    3/15/2024 - 12:03pm
  • Gilead announces expiration of HSR waiting period for CymbaBay tender offer

    3/11/2024 - 08:41am
  • Merus price target raised by $8 at BofA, here's why

    3/8/2024 - 07:47am
  • Gilead says Biktarvy demonstrates high rates of viral suppression

    3/6/2024 - 16:32pm
  • Gilead, Merck announce Phase 2 data on islatravir-lenacapavir combination

    3/6/2024 - 10:28am
dynamic_feed Breaking News